ライフサイエンスコーパス: injection site

1 Nef as clade B consensus sequences (separate injection sites).

2 iunit best frequency was determined for each injection site.

3 as arginase-1, IDO1, PDL1, and IL-10 at the injection site.

4 ainful and the effects are restricted to the injection site.

5 fection from the initial peripheral mosquito injection site.

6 al residue or adverse tissue reaction at the injection site.

7 , chills, headache, myalgia, and pain at the injection site.

8 ut also long-term antigen persistence at the injection site.

9 avoidable) subcutaneous phototoxicity at the injection site.

10 e release of a biopharmaceutical from the SC injection site.

11 ) lymph node (LN) and the distal LN from the injection site.

12 and pigs with minimal local reaction at the injection site.

13 nly subjective symptom was local pain at the injection site.

14 initiates inflammatory events locally at the injection site.

15 igration of contrast agents from the initial injection site.

16 on of mild subconjunctival hemorrhage at the injection site.

17 s and nausea, and ulceration and pain at the injection site.

18 ced more rapid neutrophil recruitment to the injection site.

19 , chills, headache, myalgia, and pain at the injection site.

20 slow release kinetics from the subcutaneous injection site.

21 nal cord response, not observed at the nerve injection site.

22 developed a grade 3 erythematous rash at the injection site.

23 ly immunocompromised NSG mice by varying the injection site.

24 al pole, but typically, not through the ICSI injection site.

25 lymphatic and blood capillaries draining the injection site.

26 n the ability to recruit immune cells to the injection site.

27 lateral substantia nigra and adjacent to the injection site.

28 hat the ExoA activity was significant at the injection site.

29 onses but reduced skin reactogenicity at the injection site.

30 th cationic liposomes forming a depot at the injection site.

31 re probably related to remnants of tracer at injection sites.

32 lling in each eye, representing a total of 6 injection sites.

33 -validated model estimated on only the other injection sites.

34 their actual location with that predicted by injection sites.

35 a function of distance between the cortical injection sites.

36 rprisingly, is observed for a broad range of injection sites.

37 bleeding time, and vascular leakage at skin injection sites.

38 Near the injection site, a significant portion of alphaS inclusio

39 (13/62) of placebo recipients reported >/=1 injection-site adverse events (AEs), and 52% (149/289) a

40 More injection-site adverse events occurred with inclisiran t

41 n and placebo groups in each trial, although injection-site adverse events were more frequent with in

42 articipants who received ID vaccine had mild injection-site AEs compared with participants who receiv

43 Solicited AEs included injection-site AEs from days 1 to 5, and joint pain, joi

44 e chorioretinal atrophy was developed at the injection site after a single, standard low-dose intravi

45 Extravasation at the injection site and accumulation in central catheters can

46 ctivity and potential toxicities both at the injection site and beyond.

47 curred rapidly and transiently at the muscle injection site and draining lymph node postinjection, co

48 coll was also preferentially retained at the injection site and draining lymph nodes and produced few

49 induction of innate immune responses at the injection site and draining lymph nodes.

50 nflammatory reaction limited to subcutaneous injection site and elicited no other toxic effects.

51 ins (NF2, NF3, and NF4) were confined to the injection site and eventually cleared.

52 ons of the B. burgdorferi populations at the injection site and in distal tissues determined.

53 mechanism contributes to persistence at the injection site and in draining lymph nodes.

54 ion in terms of interferon expression at the injection site and in draining lymphoid tissue compared

55 rved the dynamics of the mRNA vaccine at the injection site and in the draining lymph nodes, performe

56 GBS67-CpGODN+L formed a vaccine depot at the injection site and induced a remarkable increase of func

57 efficacy in paralyzing local muscles at the injection site and lower systemic diffusion, thus extend

58 adverse events within 28 days, and solicited injection site and systemic reactogenicity on the day of

59 ased physiological buffer that mimics the SC injection site and the infinite sink of the body.

60 djuvants were retained preferentially at the injection site and the nearest draining lymph nodes comp

61 The retention of the vehicles at the injection site and the release rate were determined pred

62 Injection site and the tumor markers human epidermal gro

63 muscle layer under the perianal skin at the injection site and then diffused out over time.

64 rtment simulates the drug migration from the injection site and uptake by the blood and/or lymph capi

65 Radioactivity at the T cell injection sites and in the thigh (background) was measur

66 Injection-site and systemic adverse events (AEs) and vac

67 ally well-tolerated, with increased rates of injection-site and systemic AEs compared to placebo, and

68 Transient, mild-to-moderate injection-site and systemic AEs were reported more frequ

69 ary endpoints were frequency and severity of injection-site and systemic reactions within 28 days of

70 Solicited reports of injection-site and systemic reactions within 7 days afte

71 tegrity, enhances immune infiltration at the injection site, and leads to a potent immune response ag

72 =40 [60%]) or tenderness (n=32 [47%]) at the injection site, and the most frequent systemic reactogen

73 s as a function of distance between cortical injection sites, and found that there was a highly regul

74 to PsACWY (1996 subjects), tenderness at the injection site appeared to be more frequent in the PsA-T

75 t the two tracers behave very similarly when injection sites are well matched.

76 cells could not be promptly recruited to the injection site before the injected cGAMP was diffused ou

77 ultiple locations that were distant from the injection site but within the confines of the bleb creat

78 M-MDSCs infiltrated the vaccine injection site, but not vaccine-draining lymph nodes.

79 myelinating lesions were not centered on the injection site, but rather formed 1 week later at the wh

80 recruitment of multiple immune cells at the injection site, but their cellularity and phenotypes wer

81 the delivery of therapeutics to the desired injection site by syringes and hollow needles typically

82 g of these cases reveals that the centers of injection sites can be reconstructed, on average, to wit

83 We investigated how the injection site chosen for vaccination dictates CD8 T cel

84 vealed that DDA-cLNPs remained longer at the injection site compared to DOTAP-cLNPs and iLNPs when ad

85 present in the hemisphere ipsilateral to the injection site compared to the contralateral hemisphere.

86 tesamorelin group experienced more localised injection site complaints than those in the placebo grou

87 howed that the projection zone of a cortical injection site could be predicted with considerable accu

88 lution) was performed in 9 eyes, followed by injection site cryotherapy.

89 nflammation that persists over months at the injection site, degradable PSC7A primes a transient acut

90 After 1 month, the retina around the injection site demonstrated diffuse retinal pigment epit

91 ed in vaccines for antigen stabilization and injection site deposition.

92 concomitant triple-freeze cryotherapy at the injection site during needle withdrawal for prevention o

93 eaction in 445 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 2

94 o, the most common adverse events were again injection-site erythema (33 [8%] of 416 with 50 mg siruk

95 of patients in the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group)

96 st common adverse events in this period were injection-site erythema (four [1%] with placebo, 22 [8%]

97 ifferences between administration routes for injection-site erythema (n=10 [12%] and n=0, respectivel

98 possibly related to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolyti

99 Injection-site erythema was the most commonly coded term

100 polyps and asthma, headache, epistaxis, and injection-site erythema) were more frequent with placebo

101 by short-term, mild-to-moderate pain at the injection site, fatigue, and headache.

102 Local reactions at the injection site following PrEP and PEP were mild and tran

103 Local reactions at the injection site following primary vaccination were mild a

104 nd VEEV at 12 h postinoculation (hpi) at the injection site (footpad) and as early as 72 hpi in the b

105 remain viable but permanently dormant at the injection site for nearly a year, whereas the expression

106 ith PEG-PLLA copolymer were preserved at the injection site for weeks and months indicating extremely

107 ), dizziness (2%), nasopharyngitis (1%), and injection site hematoma (1%).

108 Only 1 adverse event (mild injection site hematoma) was assessed as treatment-relat

109 ibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively.

110 Epicardial pacing of the injection site identified matching beats arising from th

111 ted on the following topics: spacing between injection sites (ie, vaccine spacing), site of injection

112 5/tCO2) was 190x larger than for the farther injection site, illustrating how careful siting would mi

113 With the exception of minor bleeding at the injection site in a few animals injected either by jet i

114 ulted in Ca(2+)-driven PVCs arising from the injection site in all hearts studied.

115 oviding detectable levels of EPO-R76E at the injection site in the eye in vivo for at least 28 days.

116 l as in its elimination at the intramuscular injection site in vivo during mixed infection, with over

117 s with Th1-dominant cytokine profiles at the injection site in vivo.

118 of the cells were ipsilateral to Fluoro-Gold injection sites in both the RVLM and CVLM, and the remai

119 in ventricular myocytes near the adenovirus-injection sites in Langendorff-perfused intact working h

120 als were also observed contralateral to mPFC injection sites in rats, appearing as a less dense "mirr

121 tion from different FC regions varied across injection sites in strength, following different spatial

122 The injection sites included representations ranging from th

123 y, the nano-suspension formed a depot at the injection site, inducing localized immune responses with

124 also activate Mrgprb2 and MRGPRX2, and that injection-site inflammation is absent in mutant mice.

125 Patient age and weight, new injection site location, addition of topotecan, concomit

126 The injection site locations ranged from 2 degrees to 10 deg

127 lution, and the thrombus was either near the injection site (M1) or flushed into the superior divisio

128 buted, up to 10 mm antero-posterior from the injection site, mainly dorsal to the putamen in the exte

129 icardially into predetermined areas and each injection site marked.

130 tance of the [4Fe-4S] cluster as an electron injection site, modulating the redox potential and the c

131 Injection site morphology and serum cytokine levels did

132 Pain at the injection site, mostly grade 1 and grade 2, was the most

133 steeply with rostrocaudal distance from the injection sites, much more so than following perirhinal

134 5% of patients in any group) were diarrhoea, injection-site nodules, nausea, and urinary tract infect

135 rom countries over acceptability of multiple injections, sites of administration, and safety.

136 no evidence of VGX-6150 accumulation at the injection site or in any organ 1 month following the 14(

137 Severe injection site or systemic events were uncommon.

138 These abnormalities were found at the injection site or within the meridian of the injection a

139 l water quality, either from those deep HVHF injection sites or from the surface or shallow subsurfac

140 salt aluminum hydroxide (alum) at the muscle injection site over multiple timepoints.

141 issue damage was observed at the collagenase injection site over time, and was associated with locali

142 (P = 0.54), physician experience (P = 0.23), injection site (P = 0.41), caliper use (P = 0.75), or 31

143 Vaccinees reported injection site pain (52% vs 17%) and erythema (73% vs 25

144 events related to NBTXR3 administration were injection site pain (four [4%] of 89) and hypotension (f

145 cited local and systemic adverse events were injection site pain (frequency, 70%, 66%, and 42% per do

146 The most frequent solicited local AE was injection site pain (frequency, 78%, 63%, and 33% per do

147 Headache (in clinical trials) and injection site pain (postapproval) were the most commonl

148 Injection site pain occurred more frequently with adjuva

149 Injection site pain was the most common adverse event, r

150 LRs (primarily injection site pain) were more frequent in vaccine recip

151 ly with LY2951742 than with placebo included injection site pain, erythema, or both (21 [20%] of 107

152 Injection site pain, itching, and erythema (mostly mild)

153 Local reactions were mainly injection site pain/tenderness, with no reported fever o

154 group (n=10 [48%]; p=0.0049), mostly due to injection-site pain (n=55 [59%]).

155 The most common adverse events were mild injection-site pain and pruritus.

156 ) of 27 Malians boosted with MVA-BN-Filo had injection-site pain or tenderness.

157 discontinuation (two [<1%] of 230 patients); injection-site pain was reported most frequently.

158 during treatment were attacks of angioedema, injection-site pain, and headache.

159 The most common adverse events were injection-site pain, fatigue, myalgia, and headache.

160 ilar in nature to those previously reported (injection-site pain, feeling feverish, muscle ache, head

161 The most frequent adverse events were injection-site pain, upper respiratory tract infection,

162 f the patients in the galcanezumab group had injection-site pain.

163 Irrespective of the injection site (perirhinal or temporal neocortex) and ta

164 lso induced in brain regions distal from the injection site, predominantly in neurons.

165 ausea (16 [8%] vs 18 [9%] vs five [5%]), and injection-site pruritis (19 [9%] vs 13 [6%] vs four [4%]

166 Due to the dissipation of SPIOs from the injection site, quantitative mapping of SPIO distributio

167 The dye content of the injection sites ranged from 371 to 1,441 pmol, which rep

168 Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacok

169 uently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followe

170 Injection site reaction was the most commonly reported T

171 The most common adverse event was injection site reaction.

172 thma, upper respiratory tract infection, and injection site reaction.

173 e ixekizumab groups were nasopharyngitis and injection site reaction.

174 among patients who received bococizumab was injection-site reaction (12.7 per 100 person-years).

175 frequent treatment-related adverse event was injection-site reaction (nine [22%] of 41 patients).

176 ions, namely regional lymphadenitis (33.9%), injection site reactions (35.2%), osteitis/osteomyelitis

177 b vs 13 [6%] patients receiving placebo) and injection site reactions (60 [16%] vs eight [4%]) occurr

178 d placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% t

179 Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25

180 lacebo group vs 47% in the dupilumab group), injection site reactions (7% vs 40%, respectively), and

181 Common adverse events included injection site reactions (78% with mipomersen, 31% with

182 lecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7).

183 Injection site reactions (RR, 8.82; 95% CI, 5.04-15.44)

184 Injection site reactions after Tdap immunization were re

185 Injection site reactions and gastrointestinal symptoms w

186 Most AEs were mild local injection site reactions following intradermal vaccinati

187 ich was mainly because of a higher number of injection site reactions in the anakinra group.

188 Injection site reactions occurred in 20 of 106 patients

189 Adverse events were mostly injection site reactions occurring after QbG10 administr

190 mmunomodulatory mechanisms of GA and adverse injection site reactions seen in patients.

191 associated with a higher frequency of local injection site reactions than was the use of needle and

192 Injection site reactions were mild or moderate.

193 Systemic and injection site reactions were mild, transient, and simil

194 Mild injection site reactions were more common in the Cervari

195 Injection site reactions were recorded in nine (9%) pati

196 Mild injection site reactions were the most common adverse ev

197 Injection site reactions were the most common individual

198 Injection site reactions were the most frequently report

199 of mild adverse reactions (lymphadenitis and injection site reactions) were reported in vaccinees old

200 articipants having adverse events (excluding injection site reactions); no treatment-related deaths o

201 y vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermal

202 were assessed by monitoring adverse events, injection site reactions, and laboratory test results.

203 inees experienced mild-to-moderate solicited injection site reactions, compared with 47% of placebo r

204 s associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrex

205 14 treatment-related adverse events, mostly injection site reactions, occurred in five children.

206 Local injection site reactions, select systemic symptoms, and

207 ith the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse eve

208 verity of reported adverse events, including injection site reactions, were similar in the generic dr

209 the highest incidence were mild to moderate injection site reactions.

210 nemia, fatigue, thrombocytopenia, fever, and injection site reactions.

211 ommon treatment-emergent adverse events were injection site reactions.

212 related adverse events with the exception of injection site reactions.

213 iratory tract infections (33-41% vs 35%) and injection-site reactions (13-26% vs 13%).

214 events in drisapersen-treated patients were injection-site reactions (14 patients given continuous d

215 with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4%

216 both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were t

217 nes than with placebo; these events included injection-site reactions (in 28.5% of the patients in th

218 o received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild

219 eater median number of docetaxel cycles) and injection-site reactions (P<.001).

220 tidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPR

221 Local injection-site reactions among the women were more commo

222 Injection-site reactions and conjunctivitis were more co

223 most frequently reported adverse events were injection-site reactions and dizziness, which were self-

224 rticipants in the albiglutide group had more injection-site reactions and fewer gastrointestinal even

225 These results are consistent with local injection-site reactions and other known, generally mild

226 t common adverse events with rilonacept were injection-site reactions and upper respiratory tract inf

227 We noted grade 1-2 injection-site reactions in 36 (33%) of 110 patients in

228 similar in the three groups, except for more injection-site reactions in recipients in the double-dos

229 Injection-site reactions occurred in 5% of the patients

230 Injection-site reactions occurred in more patients given

231 Injection-site reactions occurred in most patients, but

232 Injection-site reactions to the drug were common.

233 Thrombocytopenia and injection-site reactions were common adverse events.

234 Injection-site reactions were common.

235 se events, and rates of hypersensitivity and injection-site reactions were low.

236 Injection-site reactions were mild (3648 [84%] of 4360 i

237 Injection-site reactions were more common in the bocociz

238 Vaccine-related injection-site reactions were more common in the vaccine

239 versus control, except for a higher rate of injection-site reactions with alirocumab.

240 Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse event

241 ubcutaneous group (mainly grade 1 or 2 local injection-site reactions).

242 he required large drug dosing volumes, local injection-site reactions, and frequency of injections.

243 igh incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was w

244 The most common adverse events were injection-site reactions, reported in 70 participants (9

245 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients w

246 eurocognitive events), with the exception of injection-site reactions, which were more common with ev

247 most frequent adverse events were mild local injection-site reactions, which were reported in all (15

248 treatment of opioid use disorder, except for injection-site reactions, which were reported in more th

249 The most common adverse events were mild injection-site reactions.

250 The most common adverse events were injection-site reactions.

251 ons with IONIS-APO(a)Rx were associated with injection-site reactions.

252 IONIS-APO(a)-LRx was associated with no injection-site reactions.

253 A85A was associated with expected mild local injection-site reactions.

254 ents (AEs) experienced by subjects were mild injection-site reactions.

255 y treatment-related adverse events were mild injection-site reactions.

256 most common adverse event in all groups was injection-site redness (up to 25% of participants).

257 ofiles of inflammatory skin reactions at the injection sites reflected an IFN-alpha-signature, wherea

258 proved survival approximately 38-fold at the injection site relative to injected isolated cells, and

259 rs from rapid and wide diffusion outside the injection site resulting in short lived benefits while c

260 Examination of the injection site revealed numerous monocytes and relativel

261 A region within 5-15 nm of the injection site shows a marked reduction in manipulation.

262 n vitro system, termed Scissor (Subcutaneous Injection Site Simulator).

263 By assaying Il1b transcripts in the injection site skin of CFA-immunized mice, we found that

264 se events (all grades) consisted of local DC injection site skin reactions (100%), transient post-DC

265 FI was of value for identification of near-injection-site SNs (two patients), SNs located in comple

266 these connections depend on the location of injection sites, so that lateral PE receives preferentia

267 ISFIs may be, in part, due to differences in injection site stiffness.

268 confirm that implant behavior is affected by injection site stiffness.

269 BMSCs that migrated from the injection site survived at the border of DRGs for more t

270 Injection-site symptoms were reported by 163 participant

271 es were performed for three post-vaccination injection-site symptoms.

272 nd was associated with more reactions at the injection site than the hepatitis A virus vaccine and sa

273 ds to the suprachoroidal space-a challenging injection site that provides access to the back of the e

274 (of both delivery system and antigen) at the injection site, the cationic emulsions did not.

275 the transcriptomic changes in muscle at the injection site, the lymph node that drained the muscle,

276 fish larvae are infected via the two primary injection sites, the hindbrain ventricle and caudal vein

277 Gene expression profiling in injection-site tissues from mice immunized with SAM-base

278 in the propagation of tau pathology from the injection site to neuroanatomically connected brain regi

279 t role in facilitating distribution from the injection site to peripheral tissues by reducing renal c

280 gen, while precipitating the allergen at the injection site to reduce the risk of anaphylaxis.

281 ranging from local skin inflammation at the injection site to systemic anaphylaxis.

282 and the spreading of tau inclusions from the injection sites to anatomically connected brain regions.

283 ocytose and process Ag, and migrate from the injection site, via the afferent lymphatic vessels, into

284 ted a faster clearance of (18)F-FLT from the injection site vs. (18)F-FDG (p </= 0.001), indicating l

285 een groups, although severity of pain at the injection site was higher for gentamicin (mean visual an

286 Pain at the injection site was more common in women given quadrivale

287 Mild-to-moderate pain or tenderness at the injection site was the most commonly reported solicited

288 In both studies, pain and tenderness at the injection site was the most frequent local symptoms (37

289 T cells; (124)I-iodide uptake at the T cell injection site was time-dependent and associated with hi

290 d by aluminum hydroxide nanoparticles in the injection sites was milder than that induced by micropar

291 of regions of interest, and the location of injection sites was reconstructed relative to cytoarchit

292 Pain at the injection-site was the most common local reaction.

293 hree mosaics each (each region at a separate injection site) was compared to a whole-protein vaccine

294 Adverse events related to injection site were more common in the 9vHPV group than

295 Microstimulation and tracer injection sites were verified histologically to be locat

296 matory skin reactions at pegylated IFN-alpha injection sites, were analyzed for the expression of rel

297 n the lymphatic vessels that connect an i.m. injection site with the local lymph node has not been in

298 stabilized nanodroplets disappeared from the injection site within 48h.

299 Injection sites within S1 were matched so that direct co

300 ear was found located in the quadrant of the injection site (within 1.5 clock hours of the injection)